Stephens L A, Kay T W
Burnet Clinical Research Unit, Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Int Immunol. 1995 Dec;7(12):1885-95. doi: 10.1093/intimm/7.12.1885.
Expression of the co-stimulatory molecule B7-1 (CD80) on pancreatic beta cells can overcome peripheral T cell tolerance in transgenic models of autoimmune disease. This study aimed to determine if aberrant B7-1 or B7-2 (CD86) expression on pancreatic beta cells is involved in the pathogenesis of autoimmune diabetes in non-obese diabetic (NOD) mice. Immunohistochemical analysis of NOD pancreas sections revealed no evidence of B7-1 or B7-2 expression on pancreatic beta cells at any stage prior to the onset of either spontaneously arising or cyclophosphamide-accelerated diabetes. Likewise, the NOD-derived NIT-1 beta cell line did not express surface B7 or B7-1 mRNA either constitutively or following exposure to IFN-gamma and TNF-alpha, two cytokines known to be present in the insulitis lesion of NOD mice, or cAMP which can induce B7-1 expression on B cells. Both B7-1 and B7-2 were, however, highly expressed on the majority of islet-infiltrating inflammatory cells in NOD mice between days 7 and 12 after the administration of cyclophosphamide which results in accelerated beta cell destruction. Likewise B7-1 and B7-2 were extensively expressed on islet-infiltrating cells present at the time of diabetes onset in NOD SCID mice with adoptively transferred diabetes. By immunohistochemistry and flow cytometry, it was determined that the phenotype of B7+ cells in the pancreas of NOD mice 9 days after cyclophosphamide included a mixture of macrophages and both CD4+ and CD8+ T cells. B7-2 was also expressed on islet-infiltrating cells in the spontaneously occurring diabetes of female NOD mice, but the levels of B7-1 expression were low in comparison with the accelerated models of diabetes. RIP-IL-2 transgenic mice, which have extensive islet infiltration but no autoimmune beta cell destruction, also had virtually no B7-1 expression and a minority of B7-2-expressing inflammatory cells. Thus, the activation of beta cell-specific T cells in NOD mice does not appear to be a result of aberrant expression of B7 on the beta cells. Expression of B7-1 and B7-2 on islet-infiltrating cells is, however, associated with autoimmune beta cell destruction, suggesting a role for the B7-CD28 interaction in this process.
在自身免疫性疾病的转基因模型中,共刺激分子B7-1(CD80)在胰腺β细胞上的表达可克服外周T细胞耐受性。本研究旨在确定胰腺β细胞上异常的B7-1或B7-2(CD86)表达是否参与非肥胖糖尿病(NOD)小鼠自身免疫性糖尿病的发病机制。对NOD胰腺切片进行免疫组织化学分析发现,在自发性或环磷酰胺加速性糖尿病发病前的任何阶段,胰腺β细胞上均无B7-1或B7-2表达的证据。同样,源自NOD的NIT-1β细胞系无论是组成性表达还是在暴露于IFN-γ和TNF-α(已知存在于NOD小鼠胰岛炎病变中的两种细胞因子)或可诱导B细胞上B7-1表达的cAMP后,均不表达表面B7或B7-1 mRNA。然而,在给予环磷酰胺导致β细胞加速破坏后的第7至12天,NOD小鼠中大多数胰岛浸润性炎症细胞上均高表达B7-1和B7-2。同样,在过继转移糖尿病的NOD SCID小鼠糖尿病发病时存在的胰岛浸润细胞上也广泛表达B7-1和B7-2。通过免疫组织化学和流式细胞术确定,环磷酰胺处理9天后NOD小鼠胰腺中B7 +细胞的表型包括巨噬细胞以及CD4 +和CD8 + T细胞的混合物。在雌性NOD小鼠的自发性糖尿病中,胰岛浸润细胞上也表达B7-2,但与加速性糖尿病模型相比,B7-1的表达水平较低。RIP-IL-2转基因小鼠有广泛的胰岛浸润但无自身免疫性β细胞破坏,其几乎也不表达B7-1,仅有少数表达B7-2的炎症细胞。因此,NOD小鼠中β细胞特异性T细胞的激活似乎不是β细胞上B7异常表达的结果。然而,胰岛浸润细胞上B7-1和B7-2的表达与自身免疫性β细胞破坏相关,提示B7-CD28相互作用在此过程中发挥作用。